Innovacell Signs US Commercialization Deal With EVERSANA

TOKYO, Jul 23 (Pulse News Wire) – Innovacell (504A.T) announced today that its board approved a commercialization agreement with EVERSANA Life Science Services, LLC for its cell therapy product ICEF15 targeting urinary incontinence. Under the deal, Innovacell retains rights to ICEF15 while leveraging EVERSANA's infrastructure for faster US market entry.

Key benefits include reduced launch costs and aligned incentives tied to sales performance. The agreement covers strategic planning, patient education, and distribution management. Innovacell will maintain control over product rights and revenue, ensuring higher profit margins.

EVERSANA gains access to Innovacell’s pipeline and strengthens its presence in regenerative medicine. Both companies expect shared risk and return through this partnership, aiming for sustained growth. CEO Colin Novick noted EVERSANA's expertise aligns well with Innovacell's goals, positioning them as ideal partners for ICEF15's US expansion.